Akt as a Potential Prognostic Marker in Neuroendocrine Tumors: A Possibility?
- 16 November 2016
- journal article
- Published by Taylor & Francis in International Journal of Endocrine Oncology
- Vol. 3 (4) , 281-284
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Prognostic and Predictive Markers in Medullary Thyroid CarcinomaEndocrine Pathology, 2012
- Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogsOncoTargets and Therapy, 2012
- Immunohistochemical Evidence of Dysregulation of the Mammalian Target of Rapamycin Pathway in Primary and Metastatic PheochromocytomasUrology, 2012
- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR InhibitorsClinical Cancer Research, 2012
- Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR PathwayNeuroendocrinology, 2012
- Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumorsExperimental and Therapeutic Medicine, 2011
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR PathwayJournal of Clinical Oncology, 2010
- Activation of Akt Predicts Poor Outcome in NeuroblastomaCancer Research, 2007
- Epidermal Growth Factor Receptor Expression and Activation in Neuroendocrine TumoursJournal of Neuroendocrinology, 2006
- Enhanced protein kinase B/Akt signalling in pituitary tumoursEndocrine-Related Cancer, 2005